122 related articles for article (PubMed ID: 21898500)
1. Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy.
Jazayeri SM; Alavian SM
Hepatology; 2011 Nov; 54(5):1889; author reply 1889-90. PubMed ID: 21898500
[No Abstract] [Full Text] [Related]
2. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
Hsu CW; Yeh CT
Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus mutants associated with hepatitis B surface antigen loss: chicken or egg?
Tseng TC; Kao JH
Hepatology; 2012 Feb; 55(2):656-7. PubMed ID: 21969004
[No Abstract] [Full Text] [Related]
4. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.
Houlihan DD; Hopkins LJ; Suresh SX; Armstrong MJ; Newsome PN
Hepatology; 2011 Nov; 54(5):1891-2; author reply 1892. PubMed ID: 21987440
[No Abstract] [Full Text] [Related]
5. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
6. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
[TBL] [Abstract][Full Text] [Related]
7. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
Yang F; Wu XF; Li XH; Wei N
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
[No Abstract] [Full Text] [Related]
10. Predicting treatment outcomes for HBV patients.
AIDS Patient Care STDS; 2009 Mar; 23(3):223. PubMed ID: 19480059
[No Abstract] [Full Text] [Related]
11. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
12. Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.
Hadziyannis SJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):842-3; discussion 843-4. PubMed ID: 22404402
[No Abstract] [Full Text] [Related]
13. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
14. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
15. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
[TBL] [Abstract][Full Text] [Related]
17. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Ma H; Yang RF; Wei L
J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
Moucari R
J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
[No Abstract] [Full Text] [Related]
19. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
20. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
Chu CJ; Lee SD
J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
